Market Cap 227.47M
Revenue (ttm) 59.35M
Net Income (ttm) -65.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -109.99%
Debt to Equity Ratio 0.71
Volume 295,700
Avg Vol 958,098
Day's Range N/A - N/A
Shares Out 90.27M
Stochastic %K 81%
Beta 2.50
Analysts Strong Sell
Price Target $7.08

Company Profile

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with A...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 421 8100
Address:
200 Penobscot Drive, Redwood City, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 10:35 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CDXS Current Share Price: $2.54 Contracts: $CDXS March 20, 2026 $5 Calls Scale in: $0.18- $0.22 Scale out: $0.28-$0.36 Can Easily Capture: 60% ROI Blended DTE: 168 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 3 at 8:34 PM
$CDXS $BCHMF 18 new positions in CA for Bachem, if this doesn't signify something BIG I dunno what does! The chemist position is telling speaking directly to an unnamed API! https://www.ziprecruiter.com/co/Bachem/Jobs
0 · Reply
djohndjohn
djohndjohn Oct. 3 at 7:55 PM
$CDXS Dilly is shaping up to be a real Loser. No information now until Q3 earnings call (Quite period) Seems like he thinks it's a good Idea to sell ATM shares and dilute shareholders ownership at low prices. Never seen something so irresponsible.
2 · Reply
djohndjohn
djohndjohn Oct. 3 at 7:47 PM
$CDXS Finger, you block me because I ask for proof and you just ignore. The reason they don't highlight the Webinar is because it was given at TIDES US in May. It just warmed over stuff. Doesn't look like anything new at TIDES EU 2025 Spotlight Presentation with Bachem Title: Efficient Large-scale siRNA Manufacturing: Enzymatic Ligation of Short RNA Fragments Reason to attend: Linear synthesis by continuous-flow SPOS is the current state-of-the-art technology to manufacture oligonucleotide APIs. A very promising alternative, especially to manufacture large quantities, is the enzymatic ligation of short oligonucleotide fragments. This approach offers several advantages compared to the conventional strategy like higher yields and reduced purification burdens. Bachem and Codexis will present a case study When: Tuesday, May 20, 12:05-12:35pm Where: Mission Beach, Level 3 About the Speaker Arne Berthelmann, Senior Director Oligonucleotide R & D Learn more about the talk and speaker below.
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 3 at 3:34 PM
$CDXS $BCHMF NOTE what it says: "Efficient Large-scale SiRNA Manufacturing" Why hasn't Codexis highlighted this webinar? Very suspect to say the least! https://www.bachem.com/event/webinar-efficient-large-scale-sirna-manufacturing-enzymatic-ligation-of-short-rna-fragments/
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 3 at 2:06 PM
$CDXS Have a feeling they are on the presipence of a major announcement with $BCHMF regarding US production of Inclisiran. Mark this post!
0 · Reply
Jiggitus23
Jiggitus23 Oct. 2 at 9:49 PM
$CDXS dollar says thy pound us tomorrow
0 · Reply
buymoremakemore
buymoremakemore Oct. 2 at 9:45 PM
$CDXS they pulled ALNY’s tv ad. Soon there will be more attention towards SiRNA. Again this is about being patient. Partnership/BO could happen any time. The demand is there.
0 · Reply
TheHowlingMadness
TheHowlingMadness Oct. 2 at 5:13 PM
$CDXS this continues to be a piece of dogshit and yet something like dna keeps running. Makes sense. Smh
0 · Reply
Wealth_
Wealth_ Oct. 2 at 11:11 AM
0 · Reply
Latest News on CDXS
Codexis to Participate in Cantor Global Healthcare Conference

Aug 28, 2025, 9:00 AM EDT - 5 weeks ago

Codexis to Participate in Cantor Global Healthcare Conference


Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:57 PM EDT - 7 weeks ago

Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript


Codexis Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 4:05 PM EDT - 7 weeks ago

Codexis Reports Second Quarter 2025 Financial Results


Codexis to Participate in Jefferies Global Healthcare Conference

May 21, 2025, 4:05 PM EDT - 4 months ago

Codexis to Participate in Jefferies Global Healthcare Conference


Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

May 14, 2025, 6:50 PM EDT - 5 months ago

Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript


Codexis Reports First Quarter 2025 Financial Results

May 14, 2025, 4:05 PM EDT - 5 months ago

Codexis Reports First Quarter 2025 Financial Results


Codexis to Report First Quarter 2025 Financial Results on May 14

Apr 30, 2025, 4:05 PM EDT - 5 months ago

Codexis to Report First Quarter 2025 Financial Results on May 14


Codexis Announces New Employment Inducement Grants

Mar 7, 2025, 4:05 PM EST - 7 months ago

Codexis Announces New Employment Inducement Grants


Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:20 PM EST - 7 months ago

Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript


Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

Feb 6, 2025, 4:05 PM EST - 8 months ago

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board


Codexis Appoints Christos Richards to Board of Directors

Jan 16, 2025, 4:05 PM EST - 9 months ago

Codexis Appoints Christos Richards to Board of Directors


Codexis to Participate in Upcoming Healthcare Conferences

Nov 4, 2024, 4:05 PM EST - 11 months ago

Codexis to Participate in Upcoming Healthcare Conferences


Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 10:48 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript


Codexis Publishes FY2023 Sustainability Disclosures

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Codexis Publishes FY2023 Sustainability Disclosures


Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 11:01 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript


Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript

May 2, 2024, 8:24 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript


Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 10:39 PM EST - 1 year ago

Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript


LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 10:35 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CDXS Current Share Price: $2.54 Contracts: $CDXS March 20, 2026 $5 Calls Scale in: $0.18- $0.22 Scale out: $0.28-$0.36 Can Easily Capture: 60% ROI Blended DTE: 168 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 3 at 8:34 PM
$CDXS $BCHMF 18 new positions in CA for Bachem, if this doesn't signify something BIG I dunno what does! The chemist position is telling speaking directly to an unnamed API! https://www.ziprecruiter.com/co/Bachem/Jobs
0 · Reply
djohndjohn
djohndjohn Oct. 3 at 7:55 PM
$CDXS Dilly is shaping up to be a real Loser. No information now until Q3 earnings call (Quite period) Seems like he thinks it's a good Idea to sell ATM shares and dilute shareholders ownership at low prices. Never seen something so irresponsible.
2 · Reply
djohndjohn
djohndjohn Oct. 3 at 7:47 PM
$CDXS Finger, you block me because I ask for proof and you just ignore. The reason they don't highlight the Webinar is because it was given at TIDES US in May. It just warmed over stuff. Doesn't look like anything new at TIDES EU 2025 Spotlight Presentation with Bachem Title: Efficient Large-scale siRNA Manufacturing: Enzymatic Ligation of Short RNA Fragments Reason to attend: Linear synthesis by continuous-flow SPOS is the current state-of-the-art technology to manufacture oligonucleotide APIs. A very promising alternative, especially to manufacture large quantities, is the enzymatic ligation of short oligonucleotide fragments. This approach offers several advantages compared to the conventional strategy like higher yields and reduced purification burdens. Bachem and Codexis will present a case study When: Tuesday, May 20, 12:05-12:35pm Where: Mission Beach, Level 3 About the Speaker Arne Berthelmann, Senior Director Oligonucleotide R & D Learn more about the talk and speaker below.
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 3 at 3:34 PM
$CDXS $BCHMF NOTE what it says: "Efficient Large-scale SiRNA Manufacturing" Why hasn't Codexis highlighted this webinar? Very suspect to say the least! https://www.bachem.com/event/webinar-efficient-large-scale-sirna-manufacturing-enzymatic-ligation-of-short-rna-fragments/
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 3 at 2:06 PM
$CDXS Have a feeling they are on the presipence of a major announcement with $BCHMF regarding US production of Inclisiran. Mark this post!
0 · Reply
Jiggitus23
Jiggitus23 Oct. 2 at 9:49 PM
$CDXS dollar says thy pound us tomorrow
0 · Reply
buymoremakemore
buymoremakemore Oct. 2 at 9:45 PM
$CDXS they pulled ALNY’s tv ad. Soon there will be more attention towards SiRNA. Again this is about being patient. Partnership/BO could happen any time. The demand is there.
0 · Reply
TheHowlingMadness
TheHowlingMadness Oct. 2 at 5:13 PM
$CDXS this continues to be a piece of dogshit and yet something like dna keeps running. Makes sense. Smh
0 · Reply
Wealth_
Wealth_ Oct. 2 at 11:11 AM
0 · Reply
Tacto
Tacto Oct. 2 at 10:51 AM
$CDXS Money flow is negative, day after day.. Inflow: 254.13 Outflow: 329.19 And, daily short volume was 46%, so the ATM was running yet again, and this goes on every day now.. .
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 2 at 8:20 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CDXS Current Share Price: $2.50 Contracts: $CDXS March 20, 2026 $2 Calls Scale in: $0.65- $0.79 Scale out: $1.00-$1.29 Can Easily Capture: 60% ROI Blended DTE: 170 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
buymoremakemore
buymoremakemore Oct. 1 at 7:48 PM
$CDXS PLX was stale for a while but out of nowhere went back up. Can happen here
0 · Reply
Jiggitus23
Jiggitus23 Oct. 1 at 6:48 PM
$CDXS I’m so bored
0 · Reply
Bondra
Bondra Oct. 1 at 3:17 PM
$CDXS What does it mean when its green?
1 · Reply
Fingerlickengood
Fingerlickengood Oct. 1 at 1:32 PM
$CDXS $NVS That being said the COO at Novartis, Steffen Lang, sits on the BoD at Bachem....interesting coincidence! https://www.novartis.com/about/executive-committee/steffen-lang
2 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 1 at 12:28 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CDXS Current Share Price: $2.44 Contracts: $CDXS March 20, 2026 $2 Calls Scale in: $0.62- $0.76 Scale out: $0.97-$1.25 Can Easily Capture: 60% ROI Blended DTE: 170 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Wealth_
Wealth_ Sep. 30 at 6:43 PM
$CDXS 2.50$ =
1 · Reply
Fingerlickengood
Fingerlickengood Sep. 30 at 4:27 PM
$NVS You gotta wonder, where the specific enzyme was designed/synthesized that $CDXS and $BCHMF are now using in he ECO Lab to produce Inclisiran. This all seems too coincidental. https://www.codexis.com/investors/news-events/press-releases/detail/296/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 30 at 4:20 PM
$CDXS $NVS Considering the recent efforts to source all pharmaceutical drugs from manufacturers in the US to avoid heavy tariffs, and the announcement last November that Codexis and Bachem were able to efficiently manufacture Inclisiran (aka Leqvio) using an enzymatic process. I think we are well overdue for something BIG pertaining specifically to this in the near future! We will see! https://www.msn.com/en-za/news/other/jab-for-high-cholesterol-could-transform-heart-care/ar-AA1LxVYc?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 30 at 3:15 PM
$CDXS $NVS https://www.pharmacytimes.com/view/inclisiran-shows-good-toleration-and-substantial-ldl-c-reductions-in-real-world-practice
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Sep. 30 at 4:38 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CDXS Current Share Price: $2.46 Contracts: $CDXS March 20, 2026 $2 Calls Scale in: $0.54- $0.66 Scale out: $0.84-$1.08 Can Easily Capture: 60% ROI Blended DTE: 172 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply